Search

Search Constraints

You searched for: Author/Creator Benjamin, Reuben

Search Results

2. Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma. (26th September 2018)

3. Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Issue 6 (3rd May 2021)

4. Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Issue 3 (29th December 2021)

5. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Issue 10266 (12th December 2020)

6. Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. Issue 3 (17th March 2021)

8. Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. Issue 1 (18th June 2020)

9. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Issue 10262 (14th November 2020)

10. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Issue 5 (May 2021)